Rethinking cancer clinical trials for COVID-19 and beyond

The risks posed to patients with cancer by the current COVID-19 pandemic demand rapid structural changes in healthcare delivery, with many positive changes likely to continue long term. An immediate critical reassessment of trial methodology based on clinical and scientific priorities is essential t...

Descripción completa

Detalles Bibliográficos
Autores principales: Doherty, Gary J., Goksu, Mehmet, de Paula, Bruno H. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258610/
https://www.ncbi.nlm.nih.gov/pubmed/35121973
http://dx.doi.org/10.1038/s43018-020-0083-x
Descripción
Sumario:The risks posed to patients with cancer by the current COVID-19 pandemic demand rapid structural changes in healthcare delivery, with many positive changes likely to continue long term. An immediate critical reassessment of trial methodology based on clinical and scientific priorities is essential to ensure the resilience of clinical cancer research and optimize patient-centered care.

Ejemplares similares